Secondly, the mutation frequency of human epidermal growth factor receptor-2 (HER2) in PEAC is 44.4%, which is significantly higher than that in NSCLC, suggesting that anti-HER2 therapy may have a potential therapeutic effect. Here, ERBB2 is linked to non-small cell lung carcinoma.